ERBB2 and breast carcinoma: These major clinical advances were made possible by the standardization of breast cancer ERBB2-status testing by pathologists, based either on direct ERBB2 copy number assessment (by in-situ hybridization techniques) or on its validated surrogate, ERBB2 protein overexpression (by standardized immunohistostaining) [11].